Evidence map›Paper›PMID 40488513›Full record

Trial reportJournal of clinical pharmacology2025

Infliximab Pharmacokinetics, Dosing, and Response in Hospitalized Patients with COVID-19 Pneumonia: A Secondary Analysis of a Multinational Randomized Clinical Trial (ACTIV-1 IM).

Stephen J Balevic, Daniel Gonzalez, P Brian Smith, William G Powderly, Andreas Schmid, Ashley Kang, Matthew W McCarthy, Linda K Shaw, Christopher J Lindsell, Sam Bozzette and 4 more

Abstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Stephen J BalevicDuke Clinical Research Institute, Durham, NC, USA.ORCID 0000-0002-4016-1680
Daniel GonzalezDuke Clinical Research Institute, Durham, NC, USA.ORCID 0000-0001-6532-7117
P Brian SmithDuke Clinical Research Institute, Durham, NC, USA.
William G PowderlyDepartment of Medicine, Washington University St. Louis, St. Louis, MO, USA.
Andreas SchmidDeptartment of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA.
Ashley KangHackensack University Medical Center, Hackensack, NJ, USA.
Matthew W McCarthyDepartment of Medicine, Weill Cornell Medicine, New York, NY, USA.
Linda K ShawDuke Clinical Research Institute, Durham, NC, USA.
Christopher J LindsellDuke Clinical Research Institute, Durham, NC, USA.
Sam BozzetteNational Center for Advancing Translational Sciences, Bethesda, MD, USA.
Richard M W HoetelmansJohnson & Johnson Innovative Medicine, Beerse, Belgium.
Christoph P HornikDuke Clinical Research Institute, Durham, NC, USA.
Daniel K BenjaminDuke Clinical Research Institute, Durham, NC, USA.
ACTIV‐1 IM Study Group Members

Funding

COVID-19 Supplement - Center for Innovative TRIals in ChilDrEN and AdulTs (TRIDENT)U24TR001608 · NCATS · DUKE UNIVERSITY · PI BENJAMIN, DANIEL K., BERNARD, GORDON RAPHAEL · 2016 to 2022
$177.0M
UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
Project-005UL1TR001445 · NCATS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI BREDELLA, MIRIAM ANTOINETTE, HOCHMAN, JUDITH S · 2015 to 2025
$103.5M
Transform Dissemination and Implementation Science in CTSA ProgramsUL1TR002319 · NCATS · UNIVERSITY OF WASHINGTON · PI John K. Amory · 2017 to 2026
$100.0M
WU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8M
Mayo Clinic Center for Clinical and Translational Science (CCaTS UL1 Supplement - Dr. Timothy Curry)UL1TR002377 · NCATS · MAYO CLINIC ROCHESTER · PI VESNA D GAROVIC · 2017 to 2026
$78.4M
Support for QA/QC for Prior Approval ProcessUL1TR002553 · NCATS · DUKE UNIVERSITY · PI LI, JENNIFER S, MCNAMARA, JAMES O. · 2018 to 2023
$58.5M
Project-005UL1TR001430 · NCATS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BAIR-MERRITT, MEGAN H, CENTER, DAVID M. · 2015 to 2024
$52.3M
Tufts Clinical and Translational Science Institute (Pilot Supplement)UL1TR002544 · NCATS · TUFTS UNIVERSITY BOSTON · PI SELKER, HARRY P. · 2018 to 2022
$50.2M
Re-Entry Supplement: Investigation of Oral Microbial Enzymes for the Detection and Treatment of Periodontal DiseaseUL1TR002489 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BUSE, JOHN BERNARD, SHAHEEN, NICHOLAS J · 2018 to 2022
$48.6M
RADx-UP: Improving the Response of Local Urban and Rural Communities to Disparities in Covid-19 TestingUL1TR002366 · NCATS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI Mario Castro, JAMES STEVEN LEEDER · 2017 to 2026
$44.3M
National Dissemination of I-Corps@NCATS: Accelerating Translation through CommercializationUL1TR003096 · NCATS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI GUTIERREZ, ORLANDO M, KIMBERLY, ROBERT P. · 2019 to 2023
$43.6M
NCATS NIH HHS U24 TR001579NCATS NIH HHS U24 TR001608NCATS NIH HHS UL1 TR001430NCATS NIH HHS UL1 TR001445NCATS NIH HHS UL1 TR001453NCATS NIH HHS UL1 TR001881NCATS NIH HHS UL1 TR001998NCATS NIH HHS UL1 TR002319NCATS NIH HHS UL1 TR002345NCATS NIH HHS UL1 TR002366NCATS NIH HHS UL1 TR002377NCATS NIH HHS UL1 TR002489NCATS NIH HHS UL1 TR002544NCATS NIH HHS UL1 TR002553NCATS NIH HHS UL1 TR002645NCATS NIH HHS UL1 TR003017NCATS NIH HHS UL1 TR003096NCATS NIH HHS UL1 TR003107NCATS NIH HHS UM1 TR004406NIAAA NIH HHS HHSN275201000003CNIAMS NIH HHS K23 AR075874NICHD NIH HHS HHSN275201000003INICHD NIH HHS R01 HD096435
6 · The paper itself

Abstract

Infliximab may play an important role in reducing mortality in severe COVID-19, though optimal dosing is unknown. This secondary analysis of the ACTIV-1 IM trial characterized infliximab pharmacokinetics and outcomes in patients hospitalized with severe COVID-19. ACTIV-1 IM included patients admitted with COVID-19 pneumonia who received infliximab in addition to routine care. Infliximab was administered as a single 5-mg/kg intravenous dose. The primary exposure variable was predicted infliximab concentrations over 28 days (AUC

Indexed as

COVID-19 Drug TreatmentInfliximabAdultAgedArea Under CurveCOVID-19Dose-Response Relationship, DrugFemaleHospitalizationHumansMaleMiddle AgedSARS-CoV-2Treatment OutcomeInfliximabCOVID‐19infliximabpharmacokinetics

Identifiers

PMID40488513
PMCPMC12458099

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.